- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.07. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 22.07. | SINOMAB BIO-B (03681): SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 14.07. | SINOMAB BIO-B (03681): INSIDE INFORMATION UPDATE ON THE BLA FOR SM03 (SUCIRASLIMAB) IN THE TREATMENT OF RHEUMATOID ARTHRITIS | - | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE ADOPTED BY THE BOARD ON 30 JUNE, 2025 | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 JUNE 2025, APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS, CHANGE IN ... | - | HKEx | ||
| 12.06. | SINOMAB BIO-B (03681): RESIGNATION OF EXECUTIVE DIRECTOR | - | HKEx | ||
| 11.06. | SINOMAB BIO-B (03681): POSTPONEMENT AND CHANGE OF VENUE OF ANNUAL GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD | 1 | HKEx | ||
| 09.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 09.06. | SINOMAB BIO-B (03681): PASSING AWAY OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND WITHDRAWAL OF ORDINARY RESOLUTION NO. 2(D) AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 06.06. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT CESSATION TO ACT AS PRESIDENT (CHINA) | 1 | HKEx | ||
| 29.05. | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 29.05. | SINOMAB BIO-B (03681): COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 13.05. | SINOMAB BIO-B (03681): SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 24.04. | SINOMAB BIO-B (03681): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 24.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 24.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 24.04. | SINOMAB BIO-B (03681): NOTICE OF 2025 ANNUAL GENERAL MEETING | 3 | HKEx | ||
| 24.04. | SINOMAB BIO-B (03681): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD AT ROOM 3, 14/F, FAIRMONT HOUSE, 8 COTTON TREE DRIVE, CENTRAL, HONG KONG ... | 1 | HKEx | ||
| 24.04. | SINOMAB BIO-B (03681): PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES AND ... | - | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,800 | -0,86 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EVOTEC | 7,046 | -4,78 % | Fast 200 % Kurspotenzial! Evotec, Plug Power, Empire Brand Building Aktie | Erstmals haben Analysten den Newcomer Empire Brand Building unter die Lupe genommen. Sie sehen bei dem Schweizer Betreiber von Social Media- und E-Commerce-Plattformen für Familien fast 200 % Kurspotenzial.... ► Artikel lesen | |
| BIONTECH | 94,25 | -2,23 % | BioNTech Aktie: In welche Richtung wird es gehen? | © Foto: fn SymbolbildDas deutsche Biotech-Unternehmen BioNTech steht vor einer großen Veränderung. Die erfolgreiche Zeit mit Corona-Impfstoffen geht stetig weiter zu Ende. Jetzt arbeitet das Mainzer... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,945 | +2,41 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| AVIDITY BIOSCIENCES | 36,650 | -0,62 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,140 | -6,88 % | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,700 | +0,59 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| COGENT BIOSCIENCES | 11,410 | -1,13 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,350 | -1,16 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| MODERNA | 25,800 | -8,35 % | 3 Charts in 3x33 Sekunden - Heute mit Moderna, Silber und RWE | Willkommen zu '3 Charts in 33 Sekunden'! Jörg Scherer stellt uns drei Charts vor, die er aktuell ganz besonders unter die Lupe nimmt. Welche Ziele oder Signale jetzt wichtig sind, erfahren Sie im Video!... ► Artikel lesen | |
| DYNE THERAPEUTICS | 9,850 | -0,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | - Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,720 | -2,09 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| BB BIOTECH | 35,600 | +2,89 % | EQS-Adhoc: BB BIOTECH AG: BB Biotech AG veröffentlicht Zwischenbericht | EQS-Ad-hoc: BB BIOTECH AG / Schlagwort(e): Halbjahresbericht
BB Biotech AG veröffentlicht Zwischenbericht
25.07.2025 / 07:00 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 54,18 | -4,29 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,030 | -0,83 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating |
SINOMAB BIOSCIENCE LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.